The recent vigorous transnational migration of people and materials re‰ecting the development of transportation facilities, changes in social structure, and war disasters has increased the global spread of emerging and re-emerging infections. Once, as the 2009 pandemic in‰uenza A (H1N1) virus, person-to-person transmission was achieved, the spread of pandemic cannot be contained in reality. Thus enhancement of the crisis-management structure against pandemic is critically important to maintain national function. On the basis of this social background, the development of vaccination, which is the only fundamental prophylaxis, is in attention, and earliest possible establishment of system that supply mass-vaccines in a short time is required. Even if, however, rapid manufacture of vaccine antigen is actualized, there are several problems that vaccine is not easily spread across the developing country and mass vaccination is not performed immediately at the time of the crisis, because conventional vaccination is performed mainly by injection. Our research group developed transcutaneous vaccine devices; a hydrogel patch and a dissolving microneedle array which delivered antigens to antigen-presenting cells in the epidermal layer. Our transcutaneous vaccination system receives a high evaluation as novel, easy-to-use, and less-invasive vaccination method against infections from home and abroad. In this review, we introduce the research progress resulted from our basic, preclinical, and clinical study for practical use.
The patch containing 100 mg TR-OVA was put on intact auricle skin of mice. (a) Twelve hours after patch application, auricles were harvested and frozen. Frozen sections (6-mm thick) were photographed under a ‰uorescence microscope. (b) Two hours later, auricles were harvested, and then epidermal sheets were prepared. The epidermal sheets were stained with Alexa488-conjugated anti-mouse CD207. Epidermal sheet was photographed under a ‰uorescence microscope. (c) Cervical lymph nodes were harvested 48 h after 24-h patch application. Frozen lymph node sections were stained with Alexa488-conjugated anti-mouse CD207, and photographed under a ‰uorescence microscope. Hairless rats were transcutaneously vaccinated with TT alone (100 mg), DT alone (100 mg), or combined TT and DT (100 mg each) for 24 h eight times at 2-week intervals. A control group was subcutaneously immunized with combined TT and DT (100 mg each) eight times at 2-week intervals. At the indicated points, serum collected from these hairless rats was assayed for the IgG titer for (a) TT or The hydrogel patch containing TT and DT (2 mg each/5 cm×8 cm) was applied on the left brachial medial skin for 24 h. Sixty days later, the serum were collected and anti-TT (a) or DT (b) IgG titer was determined by ELISA. Open circle indicates each sample, and bar indicates geometric mean value.
Fig. 6. Micrograph of Dissolving Microneedle Arrays (MicroHyala; MH) and Antigen Localization in Skin Section
(a) Bright-ˆeld micrograph of microneedles on each MH before or after insertion into skin. Each MH was applied on the back skin of Wistar ST rats. One hour later, each MH was removed, and photographed under a stereoscopic microscope. (b) MH200, MH300, or MH800 encapsulating FITC-labeled silica particle were applied on the back skin of mice, and 6 h later skin was harvested. Frozen section were photographed under a ‰uorescence microscope. The nucleus was counterstained using DAPI (blue). Area between upper dot-line and middle dot-line; stratum corneum, area between middle dot-line and under-dot-line; living epidermis, area below under-dot-line; dermis. 
